News und Analysen
QuidelOrtho to Report Second Quarter 2023 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech completes acquisition of Polyplus
Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Acadia Healthcare Opens the First of Two Hospitals Developed in Partnership With Geisinger
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest operating joint venture hospital, Geisinger Behavioral Health Center Northeast, located in Moosic
Transgene Receives $15.3 Million from the Sale of Securities Held for Sale
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced that it has received $15.3
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
Sangamo Therapeutics, Inc. (“Sangamo”, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics (“Prevail”), a wholly
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
Inogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company has entered into a definitive
Simulations Plus Releases ADMET Predictor® 11
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of ADMET Predictor®
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of its
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has received positive recognition from leading business and industry organisations as a leading
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business
Chemed To Report Second-Quarter 2023 Earnings July 26, Related Conference Call To Be Held On July 27
Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2023, on Wednesday, July 26, 2023, following the close of trading on the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
EQS-News: Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Delaware District Court Permits NanoString’s Counterclaims that 10x Genomics and Harvard Violated the Antitrust Laws
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, provided comments on yesterday’s order of the United States District
Agilent Achieves Great Place to Work® Certification
Agilent Technologies Inc. (NYSE: A) today announced the company has achieved certification as a Great Place to Work®. The recognition reflects Agilent's commitment to creating a positive work